Engineered Bivalent Ligands to Bias ErbB Receptor-mediated Signaling and Phenotypes-Reference-Cited by-同舟云学术

Engineered Bivalent Ligands to Bias ErbB Receptor-mediated Signaling and Phenotypes

Published:2011-08 Issue:31 Volume:286 Page:27729-27740
ISSN:0021-9258
Container-title:Journal of Biological Chemistry
language:en
Short-container-title:Journal of Biological Chemistry

Author:

Jay Steven M.,Kurtagic Elma,Alvarez Luis M.,de Picciotto Seymour,Sanchez Edgar,Hawkins Jessica F.,Prince Robin N.,Guerrero Yadir,Treasure Carolyn L.,Lee Richard T.,Griffith Linda G.

Publisher

Elsevier BV

Subject

Cell Biology,Molecular Biology,Biochemistry

Reference67 articles.

1. NEW EMBO MEMBERS' REVIEW: The ErbB signaling network: receptor heterodimerization in development and cancer

2. An Open-and-Shut Case? Recent Insights into the Activation of EGF/ErbB Receptors

3. EGFR Antagonists in Cancer Treatment

4. Whither HER2-Related Therapeutics?

5. An ErbB3 Antibody, MM-121, Is Active in Cancers with Ligand-Dependent Activation

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting ERBB2 and PIK3R1 as a therapeutic strategy for dilated cardiomyopathy: A single-cell sequencing and mendelian randomization analysis;Heliyon;2024-03

2. Neuregulin-1;Cellular, Molecular, and Environmental Contribution in Cardiac Remodeling;2024

3. Neuregulin-1, a potential therapeutic target for cardiac repair;Frontiers in Pharmacology;2022-08-31

4. EGFR-targeting antitumor therapy: Neuregulins or antibodies?;European Journal of Pharmaceutical Sciences;2021-03

5. New insights into ErbB3 function and therapeutic targeting in cancer;Expert Review of Anticancer Therapy;2020-10-26